Monday, September 13, 2021
PDS Biotechnology Corp (PDSB)
Clinical Milestone Reached – Raising Price Target
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is primarily engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Raising Our Price Target. PDS Biotech announced that it has completed enrollment of the safety cohort in the Phase 2 VERSATILE-002 study. This is one of the clinical milestones we had expected in 2H21. We believe this shows development progress as well as proof-of-concept for the Versamune technology platform. We are raising our price target.
VERSATILE-002 Study Design. The Phase 2 VERSATILE-002 study is testing PDS0101 with the checkpoint inhibitor Keytruda (pembrolizumab, from Merck, MRK, $73.45, Not Rated). It is an open-label, single-arm trial testing the combination of PDS0101 with Keytruda against Keytruda alone in patients with advanced human papilloma virus-16-associated (HPV-16) head and neck cancer that has recurred or …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
